What it's for (Indications)
- Trandolapril with Verapamil HCl, marketed under various brand names such as Tarka, is primarily indicated for the treatment of essential hypertension in adult patients.
- This fixed-dose combination therapy is particularly suitable for individuals whose blood pressure is not adequately controlled with either trandolapril or verapamil monotherapy, or for whom the combination therapy is deemed appropriate as initial treatment based on a comprehensive clinical assessment of patient-specific risk factors and target blood pressure goals.
- The rationale for this combination stems from the complementary antihypertensive mechanisms of its two active components, which collectively offer enhanced blood pressure reduction and may contribute to improved patient adherence by simplifying the medication regimen.
- Its use aims to achieve and maintain recommended target blood pressure levels, thereby reducing the significant risk of cardiovascular morbidity and mortality associated with uncontrolled hypertension.
- The decision to initiate this specific combination therapy should always be made by a qualified healthcare professional after careful consideration of individual patient needs, existing comorbidities, potential drug interactions, and any contraindications to either trandolapril or verapamil.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | For trandolapril, the recommended usual dosage range for hypertension is 1 to 4 mg per day, administered in a single dose or two divided doses. For verapamil hydrochloride sustained-release tablets, the recommended usual dosage range for hypertension is 120 to 480 mg per day, administered in a single dose or two divided doses. The hazards of trandolapril are generally dose-independent, while verapamil has both dose-dependent (primarily dizziness, AV block, constipation) and dose-independent phenomena. |
Safety & Warnings
Common Side Effects
- Common side effects include hypotension, headache, cough, and dizziness.
- Other possible side effects associated with components include AV block and constipation.
- Adverse experiences with the combination product are generally mild, transient, and limited to those previously reported with verapamil or trandolapril individually.
Serious Warnings
- Black Box Warning: FETAL TOXICITY: When pregnancy is detected, discontinue trandolapril and verapamil hydrochloride extended-release tablets as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.
- Avoid during breastfeeding.
- Avoid driving or operating machinery if affected by dizziness.
- Avoid alcohol consumption while taking this medicine.
- Not recommended for patients undergoing hemodialysis or with liver impairments.
- Use with caution in patients with severe left ventricular dysfunction.
- Dose-dependent side effects of verapamil include dizziness, AV block, and constipation.
How it Works (Mechanism of Action)
The therapeutic efficacy of trandolapril with verapamil HCl arises from the synergistic and complementary actions of its two distinct antihypertensive agents, each targeting different physiological pathways involved in blood pressure regulation. Trandolapril is an angiotensin-converting enzyme (ACE) inhibitor. It exerts its primary hypotensive effect by blocking the enzyme responsible for converting inactive angiotensin I into angiotensin II, a potent vasoconstrictor and stimulator of aldosterone secretion. This inhibition leads to a reduction in systemic vascular resistance, decreased aldosterone-mediated sodium and water retention, and potentiation of the vasodilatory effects of bradykinin, an endogenous peptide. The overall result is a significant decrease in blood pressure, reduction in cardiac preload and afterload, and inhibition of detrimental cardiac and vascular remodeling processes. Verapamil HCl, on the other hand, is a non-dihydropyridine calcium channel blocker. It functions by inhibiting the influx of extracellular calcium ions through voltage-sensitive L-type calcium channels located in cardiac muscle and vascular smooth muscle cells. In the heart, verapamil decreases myocardial contractility, reduces heart rate by slowing sinus node discharge, and impairs atrioventricular (AV) nodal conduction. In vascular smooth muscle, it causes relaxation, leading to peripheral arterial vasodilation and a reduction in total peripheral resistance. When combined, trandolapril's ability to reduce circulating angiotensin II and enhance bradykinin's effects, coupled with verapamil's direct vasodilatory and cardiac depressant actions, provides a comprehensive and multi-faceted approach to blood pressure control. This dual mechanism effectively targets multiple physiological pathways involved in the pathogenesis of hypertension, optimizing the antihypertensive response while potentially mitigating some adverse effects that might be associated with higher doses of either monotherapy.